CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
“ SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. “ “ Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 “ CHARLESTOWN, Mass.,...
CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Financial Results
Solid Biosciences Announces Licensing Agreement with Armatus Bio
Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Granted FDA Orphan Drug Designation for SGT-003
CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
CHARLESTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation CHARLESTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life...